Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.60 |
| ▸ | SHBG | P04278 | 1/20 | 0.60 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.58 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27700015 | 0.86 | PIK3CA (0.74) | ESR1SHBGESR2LMNANPC1 | |
| SCHEMBL330362 | 0.80 | SHBG (0.60) | ESR1SHBGESR2LMNANPC1 | |
| SCHEMBL6847306 | 0.80 | PIK3CA (0.82) | ESR1SHBGESR2LMNANPC1 | |
| SCHEMBL3346345 | 0.79 | ESR1 (0.64) | ESR1SHBGESR2LMNANPC1 | |
| SCHEMBL16324510 | 0.75 | ESR1 (0.73) | ESR1SHBGESR2LMNANPC1 | |
| SCHEMBL30503014 | 0.75 | ESR1 (1.00) | ESR1SHBGESR2LMNANPC1 | |
| SCHEMBL312243 | 0.75 | ESR1 (1.00) | ESR1SHBGESR2LMNANPC1 | |
| SCHEMBL30204024 | 0.73 | LMNA (1.00) | ESR1SHBGESR2LMNANPC1 | |
| SCHEMBL2331741 | 0.73 | LMNA (1.00) | ESR1SHBGESR2LMNANPC1 | |
| SCHEMBL8703963 | 0.72 | PIK3CA (0.70) | ESR1SHBGESR2LMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2526941-A1 | Anti-inflammatory Modalities | Marshall Edwards, Inc. (US) | 2012-11-28 | — | — | EP | disclosed |
| EP-2526941-A1 | Anti-inflammatory Modalities | Marshall Edwards, Inc. (US) | 2012-11-28 | — | — | EP | disclosed |
| US-20120059176-A1 | ANTI-INFLAMMATORY MODALITIES | MARSHALL EDWARDS, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120059176-A1 | ANTI-INFLAMMATORY MODALITIES | MARSHALL EDWARDS, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120059176-A1 | ANTI-INFLAMMATORY MODALITIES | MARSHALL EDWARDS, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20090131513-A1 | ANTI-INFLAMMATORY MODALITIES | NOVOGEN RESEARCH PTY LTD. (AU) | 2009-05-21 | — | — | US | disclosed |
| US-20090131513-A1 | ANTI-INFLAMMATORY MODALITIES | NOVOGEN RESEARCH PTY LTD. (AU) | 2009-05-21 | — | — | US | disclosed |
| US-20090131513-A1 | ANTI-INFLAMMATORY MODALITIES | NOVOGEN RESEARCH PTY LTD. (AU) | 2009-05-21 | — | — | US | disclosed |
| EP-1861090-A1 | ANTI-INFLAMMATORY MODALITIES | Novogen Research Pty. Ltd. (AU) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006108212-A1 | ANTI-INFLAMMATORY MODALITIES | NOVOGEN RESEARCH PTY LTD (AU) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059176-A1 | ANTI-INFLAMMATORY MODALITIES | TNF, PTGES, NFKBIA | ESR1 561/4885SHBG 74/4885ESR2 97/4885 |
| US-20090131513-A1 | ANTI-INFLAMMATORY MODALITIES | TNF, PTGES, NFKBIA | ESR1 561/4885SHBG 74/4885ESR2 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.